news
Antibody effector functions are key to combatting COVID-19, finds study
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
List view / Grid view
Therapeutics
news
Compound that prevents replication of SARS-CoV-2 identified by researchers
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
news
Researchers identify three drugs that could be repurposed for COVID-19
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
news
Potential strategy to treat COVID-19-related cytokine storms identified
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
news
Hepatitis C drugs could combat SARS-CoV-2, researchers find
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
news
Researchers suggest SKI complex of SARS-CoV-2 as novel drug target
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
news
Scientists unveil virtual reality tool for COVID-19 drug development
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
article
Developing nanobodies and sybodies to combat COVID-19
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
news
Researchers develop ACE2 decoy to neutralise SARS-CoV-2
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
news
Inflammatory bowel disease drugs could combat COVID-19, study suggests
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
news
Protease inhibitor aprotinin shows promise against SARS-CoV-2 in cells
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
news
Autoantibodies and over-active neutrophils may be cause of COVID-19 blood clots
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
article
Treating cytokine storms in COVID-19 patients
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
news
Severe COVID-19 symptoms may not be caused by cytokine storm
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
news
CBD could treat inflammation caused by COVID-19, study shows
Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.